ASSESSMENT OF THE PROPOSED COMBINATION OF STALLERGENES AND GREER LABORATORIES HAS BEGUN

Antony (France), 15 April 2015 – Following the announcement on 3 March 2015 that STALLERGENES S.A. (EURONEXT Paris) had received a proposal from its majority shareholder, Ares Life Sciences, which seeks to bring together the activities of STALLERGENES and GREER LABORATORIES Inc., a US company (hereafter "GREER"), in order to form the global leader in allergen immunotherapy1, STALLERGENES' Board of Directors requested the Independent Directors Committee to review the proposal, in the interest of all shareholders.

The Independent Directors Committee has therefore begun assessing the proposal in the interest of all STALLERGENES' shareholders and, in this context, has appointed the firm Ricol Lasteyrie Corporate Finance as independent expert. It has also appointed Lazard Frères as advisory bank. The terms and conditions of the proposed transaction are also being reviewed by the firm Ledouble, appointed by the Commercial Court as Valuation Expert.

The Independent Directors Committee will inform STALLERGENES' Board of Directors of progress on these workstreams at a meeting during the first half of May.

After completion of the current information and consultation process of STALLERGENES' Works Council and following consideration of the reports mentioned above, the Board of Directors, upon the recommendation of the Independent Directors Committee and following receipt of both the valuation expert's report and the statement of fairness from the independent expert, will meet to give its decision regarding the proposed transaction after which such decision will be submitted to STALLERGENES shareholders.

Information, in particular concerning the assessment of the proposal, will then be communicated to the market in order to fully inform shareholders of the terms and conditions of the transaction prior to the Annual General Meeting called to vote on the proposal.

For these reasons, and in order to give the experts the necessary time to complete their tasks, it has been decided that the Annual General Meeting of STALLERGENES' Shareholders scheduled for 22 May will be postponed until 26 June 2015.

The transaction is also subject to certain customary conditions, notably the approval of the French tax authorities and the confirmation by the Financial Markets Authority that it will not trigger a requirement to make a public buy-out offer for STALLERGENES shares.

According to the current timetable, the transaction could take place during the third quarter of 2015, following completion of the legal formalities required for implementation.

Patrick Langlois, Chairman of STALLERGENES' Board of Directors, said:

"STALLERGENES' Board of Directors recognises the project's strategic interest for the company and its shareholders, insofar as it would strengthen the development potential of the business, and would diversify the geographic risk stemming from the high concentration of STALLERGENES' sales in Europe and capture the as yet untapped growth of the US allergen immunotherapy market. I would like to underline our commitment to include, in complete transparency, all STALLERGENES' minority shareholders in this value enhancing project."

 

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.